NCT06645938 - A Study to Learn How Different Tablets of the Study Medicine Vepdegestrant Are Taken up Into the Blood in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

February 20, 2025

Study Completion Date

March 14, 2025

Conditions

Healthy

Interventions

DRUG

single dose of vepdegestrant as tablet formulation (Treatment A)

Single 200 mg dose of vepdegestrant registrational (200 mg strength) tablet.

DRUG

single dose of vepdegestrant as tablet formulation (Treatment B)

Single 200 mg dose of vepdegestrant variant (200 mg strength) tablet.

Trial Locations (1)

Pfizer Clinical Research Unit - Brussels, Brussels